HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Further studies on the tumor-initiating activity of the beta-blocker DL-ZAMI 1305.

Abstract
The purpose of this study was to evaluate the initiating activity of the hepatocarcinogen beta-blocker DL-1-(2-nitro-3-methyl-phenoxy)-3-tert-butylamino-propan-2-ol (DL-ZAMI 1305) by the initiation-promotion protocol of Pereira. Female Wistar rats were given a single dose 150 mg/kg of body weight of DL-ZAMI 1305 by gavage 24 hours before or 24 hours after partial hepatectomy. One week later rats were given phenobarbital (0.05%) in the diet for a period of 7 weeks. DL-ZAMI 1305-treatment resulted in the appearance of gamma-glutamyltranspeptidase foci and of other preneoplastic lesions in all animals. Preneoplastic lesions were also present in a fraction of DL-ZAMI 1305-treated animals not subjected to partial hepatectomy, whether given or not phenobarbital. Results obtained in a separate experiment demonstrated that DL-ZAMI 1305-treatment inhibits cell proliferation and induces DNA damage in the regenerating rat liver. The results of this study clearly demonstrated that the beta-blocker DL-ZAMI 1305 is an initiating carcinogen for the liver of female Wistar rats.
AuthorsN Pacces, M Braga, T Zavanella, M Presta, G Ragnotti
JournalToxicologic pathology (Toxicol Pathol) Vol. 14 Issue 4 Pg. 470-6 ( 1986) ISSN: 0192-6233 [Print] United States
PMID2880384 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic beta-Antagonists
  • Propanolamines
  • ZAMI 1305
  • DNA
  • gamma-Glutamyltransferase
Topics
  • Adrenergic beta-Antagonists (toxicity)
  • Animals
  • Cell Transformation, Neoplastic (drug effects)
  • DNA (drug effects)
  • Female
  • Liver (drug effects, pathology)
  • Liver Regeneration
  • Precancerous Conditions (chemically induced)
  • Propanolamines (toxicity)
  • Rats
  • Rats, Inbred Strains
  • gamma-Glutamyltransferase (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: